Analysts and participants in the molecular biology tools industry are predicting a stronger pharmaceutical spending market in the second half of 2005, erasing earlier concerns about potential long-term revenue declines for the sector.

The predictions, which come after a turbulent beginning of the year marked by spotty R&D spending and volatile investment in molecular biology tools, may help buoy the multi-platform business sector covered by BioCommerce Week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.